高级检索
    梁翠微, 龚五星, 杜均祥, 彭东旭. 非小细胞肺癌外周血分子微转移研究[J]. 蚌埠医科大学学报, 2011, 36(7): 709-711.
    引用本文: 梁翠微, 龚五星, 杜均祥, 彭东旭. 非小细胞肺癌外周血分子微转移研究[J]. 蚌埠医科大学学报, 2011, 36(7): 709-711.
    shu
    LIANG Cui-wei, GONG Wu-xing, DU Jun-xiang, PENG Dong-xu. Study on circulating molecular marker of micrometastasis in non-small cell lung cancer[J]. Journal of Bengbu Medical University, 2011, 36(7): 709-711.
    Citation: LIANG Cui-wei, GONG Wu-xing, DU Jun-xiang, PENG Dong-xu. Study on circulating molecular marker of micrometastasis in non-small cell lung cancer[J]. Journal of Bengbu Medical University, 2011, 36(7): 709-711.
    shu

    非小细胞肺癌外周血分子微转移研究

    Study on circulating molecular marker of micrometastasis in non-small cell lung cancer

      摘要
    • 摘要: 目的: 研究非小细胞肺癌(NSCLC)患者外周血癌胚抗原(CEA)、CK19、Lunx mRNA表达对于肿瘤微转移的价值。方法: 采用RT-PCR技术,对46例NSCLC患者(其中肺癌Ⅰ期组6例,Ⅱ期组9例,Ⅲ期组14例,Ⅳ期组17例))和同期18例良性肺部疾病(对照组)患者外周血CEA、CK19、Lunx mRNA进行检测。结果: NSCLC患者外周血Lunx、CEA、CK19 mRNA的阳性率为52.2%、43.5%、41.3%,其中Ⅰ期组Lunx、CEA和CK19 mRNA的阳性率为16.6%(1/6)、16.6%(1/6)和0%(0/6),与对照组差异均无统计学意义(P > 0.05);Ⅱ期、Ⅲ期和Ⅳ期组NSCLC患者Lunx mRNA的阳性率为44.4%(4/9)、50.0%(7/14)、70.6%(12/17),CEA mRNA的阳性率为33.3%(3/9)、50.0%(7/14)、52.9%(9/17),CK19 mRNA的阳性率为22.2%(2/9)、42.9%(6/14)、64.7%(11/17),肺癌Ⅱ期组Lunx、肺癌Ⅲ期组CEA和Lunx、肺癌Ⅳ期组CEA、CK19、LunxmRNA表达阳性与对照组差异均有统计学意义(P < 0.05~P < 0.01)。结论: 检测外周血CEA、CK19、Lunx mRNA表达可作为诊断早期NSCLC患者微转移重要的参考指标。

       

      Abstract: Objective: To explore the diagnostic value of carcinoembryonic antigen(CEA),CK19,Lunx mRNA in peripheral blood of patients for the micrometastasis in non-small cell lung cancer(NSCLC). Methods: RT-PCR was used to detect the expression of CEA, CK19,and Lunx mRNA in peripheral blood samples from 46 patients with NSCLC and 18 patients with benign pulmonary lesion. Results: The positive rates of Lunx,CEA and CK19 mRNA were 52.2%, 43.5% and 41.3% respectively in peripheral blood of patients with NSCLC. The positive rates of Lunx,CEA and CK19 mRNA in stage Ⅰ were 16.6% (1/6), 16.6% (1/6) and 0% (0/6) respectively, and they had no significant differences with control(P > 0.05). The positive rates of Lunx mRNA in stageⅡ, stage Ⅲ, and stage Ⅳ patients were 44.4% (4/9), 50.0% (7/14), and 70.6% (12/17) respectively. The positive rates of CEA mRNA were 33.3% (3/9), 50.0% (7/14) and 52.9% (9/17) respectively. The positive rates of CK19 mRNA were 22.2% (2/9),42.9% (6/14) and 64.7% (11/17) respectively. The positive rates of Lunx mRNA in stage Ⅱ,CEA mRNA and Lunx mRNA in stage Ⅲ, and Lunx, CEA, CK19 mRNA in stage Ⅳ had significant differences with control (P < 0.05-P < 0.01). Conclusions: The expressions of CEA, CK19 and Lunx mRNA in peripheral blood can be used as diagnostic biomarkers of micrometastasis in patients with NSCLC.

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回